Supplementing Intracytoplasmic Sperm Injection Handling Medium With Chaetoglobosin A ( ICSI-CA)
- Conditions
- Infertility
- Interventions
- Other: Medium Supplemented with Chaetoglobosin A
- Registration Number
- NCT03678584
- Lead Sponsor
- Ibn Sina Hospital
- Brief Summary
Vienna Consensus has identified 10% damage rate after ICSI as a competency value. Despite the highest quality embryologists doing ICSI, degeneration sometimes occurs due to oocyte factors such as the fragile membrane, etc. Chaetoglobosin A serves to facilitate spindle or pronuclear transfer procedures helping to reduce the damage rate with no harm reported. Using Chaetoglobosin A during ICSI could serve to rescue some oocytes from the degeneration allowing for more chances of viable zygotes.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 300
- All ICSI participants agreed
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Handling Medium Supplemented with Chaetoglobosin A Medium Supplemented with Chaetoglobosin A -
- Primary Outcome Measures
Name Time Method Oocyte Survival after ICSI two days Survived oocytes per MII injected
- Secondary Outcome Measures
Name Time Method Implantation rate 7 weeks sacs with a heartbeat per embryo transferred
Rate of top-quality embryo 6 days of culture Rate of top-quality embryo per fertilized oocytes
blastocyst formation and quality 6 days of culture Number of formed blastocyst and high-quality blastocyst per fertilized oocytes
Fertilization rate 6 days of culture Ongoing pregnancy rate 12 weeks blastocyst utilization rate 6 days of culture Number of transferred and vitrified embryos per fertilized oocytes
clinical pregnancy rate 7 weeks Number of pregnant women per recruited cycles
Trial Locations
- Locations (3)
IbnSina IVF Center, IbnSina Hospital
🇪🇬Sohag, Egypt
Banon Assiut
🇪🇬Assiut, Egypt
Qena Fertility Center
🇪🇬Qena, Egypt